Jonathan Rowe, PhD, MS, MA

How optimizing RBQM risk detection reduces the efforts caused by false signals.

Identifying and providing clarity on the GCP quality and risk concerns associated with DCT modalities.

Optimizing feasibility through increased data collection.

A case study by Pfizer & The Avoca Group on the development of an overarching strategy for Pfizer’s clinical trial quality metrics.